OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd announced significant progress in clinical trials for pancreatic cancer treatments, achieving 50% recruitment in both the TRIPP-FFX and PANCOSIL trials. The TRIPP-FFX trial has now randomized 40 patients to test the OncoSil™ device with standard chemotherapy, while the PANCOSIL trial treated its 10th patient with the device for non-progressive pancreatic cancer. Both milestones mark the company’s advancement towards validating the OncoSil™ device’s broader clinical applications.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.